FGFR2 and neoplasm: Comprehensive genomic profiling revealed both FGFR2 amplification and rearrangement, and off-label use of pemigatinib resulted in rapid reductions in tumor markers (CEA and CA19-9) and notable clinical improvement through five treatment cycles (approximately three months) until progression was observed both by imaging and elevation of tumor markers shortly after the fifth cycle [76].